ESMO 2024: Updates in Penile Cancer - UroToday
ESMO 2024 session on rare genitourinary cancers featured updates on penile cancer by Prof. Andrea Necchi, highlighting geographic variation in incidence, surgical indications, and treatment trends. Key updates included neoadjuvant chemotherapy recommendations and ongoing challenges in patient selection for perioperative therapy. Clinical trials like InPACT and HERCULES evaluated neoadjuvant therapies, while systemic therapy options for metastatic cases were also discussed. HPV status and tumor mutational burden (TMB) were noted to influence treatment outcomes. Ongoing research emphasizes the need for tailored approaches and clinical trial participation.
Highlighted Terms
Related News
ESMO 2024 session on rare genitourinary cancers featured updates on penile cancer by Prof. Andrea Necchi, highlighting geographic variation in incidence, surgical indications, and treatment trends. Key updates included neoadjuvant chemotherapy recommendations and ongoing challenges in patient selection for perioperative therapy. Clinical trials like InPACT and HERCULES evaluated neoadjuvant therapies, while systemic therapy options for metastatic cases were also discussed. HPV status and tumor mutational burden (TMB) were noted to influence treatment outcomes. Ongoing research emphasizes the need for tailored approaches and clinical trial participation.